Clinical trial

A Trial Evaluating the Effect of NIO752 on Tau Synthesis Measured by a Process Known as SILK

NCT06372821

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention NIO752 Find medicine records · Find other trials using this name

OTHER · Unmapped registry intervention Placebo Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

A Trial Evaluating the Effect of NIO752 on Tau Synthesis Measured by a Process Known as SILK

Design: INTERVENTIONAL · Status: RECRUITING · Phase: PHASE1

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2024-11-18

PhasePHASE1

Conditions

Alzheimer Diseaseverified · MONDO: Alzheimer disease

Autosomal Dominant Alzheimer Disease Due to Mutation of Presenilin 1 (Disorder)unresolved

Autosomal Dominant Alzheimer Disease Due to Mutation of Presenilin 2 (Disorder)unresolved

Autosomal Dominant Alzheimer Disease Due to Mutation of Amyloid Precursor Protein (Disorder)unresolved

Interventions

NIO752DRUG

PlaceboOTHER

Sponsors & collaborators

University College, Londonlead sponsor

Washington University School of Medicinecollaborator

University of Washingtoncollaborator

Alzheimer's Associationcollaborator

Sigrid Rausing Trustcollaborator

Mapped research locations

St LouisMissouri, United States1 LondonUnited Kingdom1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06372821 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.